Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5-US-WO	Int'l Appln No.: PCT/GB03/003801 Int'l Filing Date: 01 Sept 2003
	Applicant: Alan Crossman et al.	
	Filing Date: March 20, 2009	Group Art Unit: 3221

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,322,346	03/1982	Korosi et al.			
	4,452,808	06/1984	Gallagher, Jr.			
	4,513,006	04/1985	Maryanoff et al.			
	4,582,916	04/1986	Maryanoff et al.			
	4,824,860	04/1989	Owen			
	6,200,970	03/2001	Ling et al.			
	6,420,369	07/2002	Marcotte			
	6,559,293	05/2003	Almarsson et al.			
	6,583,172	06/2003	Shank			
	6,649,607	11/2003	Leventer et al.			

FOREIGN PATENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0138441	08/1988	EP				
	0900568	03/1999	EP				
	99/06408	02/1999	WO				
	01/04122	01/2001	WO				
	02/088096	11/2002	WO				
	02/094189	11/2002	WO				

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Beers et al., "The Merck Manual of Diagnosis and Therpay, 17th Edition", 1999, Merck Research Laboratories Whitehouse Station, NJ, pp. 1462-1473, XP002267011.
		Beloborodova et al., "Method of Treatment of Hypertension-Hyperkinetic form of Dyskinesia of Biliferous Ways in Young Persons", 12/27/02, Abstract, XP002266976.
		Blanchet et al., "Differing Effects of N-Methyl-D-Asparate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-Phenyl-Tetrahydropyridine Monkeys," JPET, vol. 290, no. 3, 1999, pp. 1034-1040.
		Brotchie et al, "The Effects of Tofisopam on the Actions Induced by L-DOPA Administration in the MPTP – Lesioned Non-Human Primate Model of Parkinson's Disease", Society for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Program No. 165.18, pp. 1-2, XP008026196.
		Burne et al., "The Contribution of Tremor Studies to Diagnosis of Parkinsonian and Essential Tremor: A Statistical Evaluation," Journal of Clinical Neuroscience, vol. 9, no. 3, 2002, pp. 237-242.
		Connor, "A Double-Bline Placebo-Controlled Trial of Topiramate Treatment for Essential Tremor," Neurology, 59, 2002, pp. 132-134.
		Fox et al., "Neural Mechanisms Underlying Peak-Dose Dyskinesia Induced by Levodopa and Apomorphine are Distinct: Evidence from the Effects of the Alpha$_2$ Adrenoceptor Antagonist Idazoxan," Movement Disorders, vol. 16, no. 4, 2001, pp. 642-650.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5-US-WO	Int'l Appln No.: PCT/GB03/003801 Int'l Filing Date: 01 Sept 2003
	Applicant: Alan Crossman et al.	
	Filing Date: March 20, 2009	Group Art Unit: 3221

		Henry et al., "μ- and δ-Opiad Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease," Experimental Neurology, 171, 2001, pp. 139-146.
		Kanda et al., "Combined Use of the Adenosine A_{2A} Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity by Not Dyskinesia in MPTP-Treated Monkeys," Experimental Neurology, 162, 2000, pp. 321-327.
		Konitsiotis et al, "AMPA Receptor Blockade Improves Levodopa-Induced Dyskinesia in MPTO Monkeys", Neurology, Vol. 54, No. 8, April 25, 2000, pp. 1589-1595, XP008026187.
		Levine, "Medical Treatment of Essential Tremor and Parkinson's Disease," Geriatrics, vol. 53, issue 5, May 1998, 10 pages.
		Nash et al., "Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease," Experimental Neurology, 165, 2000, pp. 136-142.
		Revutsky et al., "Prophylaxis of Meteopathological Reactions in Patients with Ischemic heart Disease and Neurocirculatory Dystonia", Vrachebnoe Delo 1988 Russia, No. 2, 1988, pp. 7-10, XP008026189.
		Skradski et al., "Topiramate Blocks Kainate-Evoke Cobolt Influx into Cultured Neurons," Epilepsia, 41 (Suppl. 1), 2000, pp. S45-S47.
		Solyom et al., "Non-Competitive AMPA Antagonists of 2,3-Benzodiazepin Type", Current Pharmaceutical Design 2002, Netherlands, Vol. 8, No. 10, 2002, pp. 913-939, XP008026188.
		Tarnawa et al, "2,3-Benzodiazepine AMPA Antagonists", Restorative Neurology and Neuroscience, 1998, Vol. 13, pp. 41-57, XP008026184.
		Wolters et al., "Parkinson's Disease," Recent Advances in Pharmacotherapy, CMAJ, vol. 140, March 1, 1989, pp. 507-513.
		Answers.com, dyskinesia, http://www.answers.com/topic/dyskinesia, printed 09/11/2008, 4 pages.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	